시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 과민성대장증후군(IBS) 치료 시장 보고서(2025년)
Irritable Bowel Syndrome (IBS) Treatment Global Market Report 2025
상품코드 : 1824399
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,430,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,294,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 12,159,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

과민성대장증후군(IBS) 치료 시장 규모는 앞으로 수년간 급성장할 것으로 예측됩니다. 2029년에는 CAGR 12.5%를 나타내 49억 달러로 성장할 것으로 예상됩니다. 예측 기간의 성장은 환자 중심의 건강 관리 모델, 미생물 요법, 건강 관리의 블록 체인, 환자보고 결과(pros), 규제 패스트 트랙 프로그램 및 의료 데이터의 상호 운용성에 기인합니다. 예측 기간의 주요 동향으로는 디지털 건강 솔루션 통합, 진단 기술 진보, R&D 투자 증가, 공동 연구 및 파트너십, 비 약물 치료의 출현 등이 있습니다.

향후 5년간의 성장률 12.5%라고 하는 예측은 전회 예측으로부터 0.2%의 소폭의 감소를 반영하고 있습니다. 이 감소는 주로 미국과 다른 국가 간의 관세의 영향 때문입니다. 관세 장벽은 이탈리아와 이스라엘에서 조달한 처방용 리팍시민과 마이크로바이옴 검사 키트의 비용을 상승시킴으로써 미국을 저해하고, IBS 전문 의료에의 액세스를 저하시키고, 소화기내과 진료 비용을 상승시킬 것으로 예측됩니다. 또한 상호관세와 무역의 긴장과 한계 증가로 인한 세계경제와 무역에 대한 악영향으로 인해 그 영향이 더욱 광범위해질 것으로 보입니다.

과민성대장증후군(IBS) 치료 시장 성장이 예상되는 배경에는 과민성대장증후군(IBS)의 유병률 증가가 있습니다. IBS는 대장에 영향을 미치는 만성 위장 장애이며, 그 유병률의 상승은 생활 습관의 악화, 건강에 해로운 식습관, 오염에 대한 노출, 스트레스 수준의 상승 등에 기인합니다. IBS의 치료는 증상을 완화하고 중증도와 빈도를 줄이고 개인의 상태를 효과적으로 관리하는 능력을 향상시키는 것을 목표로 합니다. 국제위장장애재단(IFFGD)에 따르면 2023년에는 세계 인구의 약 5-10%가 IBS를 앓았고 미국에서는 2,500만명에서 4,500만명이 걸렸습니다. 그 결과, IBS의 유병률 증가는 과민성대장증후군(IBS) 치료 시장 확대를 촉진하는 중요한 요인이 되고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

KTH
영문 목차

영문목차

Treatment for irritable bowel syndrome (IBS) involves a range of approaches and interventions directed at addressing disorders in the gastrointestinal tract, common issues that impact the stomach and intestines. The objective of IBS treatment is to alleviate symptoms such as constipation, diarrhea, and abdominal discomfort, reduce the frequency and severity of flare-ups, and enhance overall well-being.

The primary categories of drugs used in irritable bowel syndrome (IBS) treatment include lubiprostone, linaclotide, eluxadoline, rifaximin, alosetron, and others. Lubiprostone, for instance, is a medication employed in treating IBS. It functions as a selective chloride channel activator, facilitating increased fluid secretion in the intestines. The drug is indicated for IBS with constipation, IBS with diarrhea, and IBS with alternating constipation and diarrhea. These medications are distributed through various channels, including hospital pharmacies, online pharmacies, and retail pharmacies, catering to diverse end-users such as hospitals, clinics, and home care settings.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The irritable bowel syndrome (IBS) treatment market research report is one of a series of new reports from The Business Research Company that provides irritable bowel syndrome (IBS) treatment market statistics, including irritable bowel syndrome (IBS) treatment industry global market size, regional shares, competitors with an irritable bowel syndrome (IBS) treatment market share, detailed irritable bowel syndrome (IBS) treatment market segments, market trends and opportunities, and any further data you may need to thrive in the irritable bowel syndrome (IBS) treatment industry. This irritable bowel syndrome (IBS) treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The irritable bowel syndrome (ibs) treatment market size has grown strongly in recent years. It will grow from $2.79 billion in 2024 to $3.06 billion in 2025 at a compound annual growth rate (CAGR) of 9.8%. The growth in the historic period can be attributed to increasing prevalence of ibs, growing patient awareness, stress and lifestyle factors, patient advocacy and support groups, healthcare reimbursement policies.

The irritable bowel syndrome (ibs) treatment market size is expected to see rapid growth in the next few years. It will grow to $4.9 billion in 2029 at a compound annual growth rate (CAGR) of 12.5%. The growth in the forecast period can be attributed to patient-centric healthcare models, microbial therapies, blockchain in healthcare, patient-reported outcomes (pros), regulatory fast-track programs, health data interoperability. Major trends in the forecast period include integration of digital health solutions, advancements in diagnostic technologies, increased research and development investments, collaborations and partnerships, emergence of non-pharmacological therapies.

The forecast of 12.5% growth over the next five years reflects a slight reduction of 0.2% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff barriers are expected to hamper the U.S. by increasing the cost of prescription rifaximin and microbiome testing kits sourced from Italy and Israel, thereby reducing access to specialized IBS care and elevating gastroenterology practice costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The anticipated growth of the irritable bowel syndrome (IBS) treatment market is driven by the increasing prevalence of irritable bowel syndrome (IBS). IBS is a chronic gastrointestinal disorder affecting the large intestine, and its rising prevalence is attributed to poor lifestyles, unhealthy eating habits, exposure to pollution, and heightened stress levels. Treatment for IBS aims to alleviate symptoms, reduce their severity and frequency, and enhance individuals' ability to manage their conditions effectively. According to the International Foundation for Gastrointestinal Disorders (IFFGD), approximately 5-10% of the global population is expected to have IBS in 2023, with between 25 and 45 million people in the United States affected by the condition. Consequently, the growing prevalence of IBS is a key factor driving the expansion of the IBS treatment market.

The growth of the IBS treatment market is expected to be propelled by the aging population. The aging population refers to a demographic trend characterized by an increasing proportion of elderly individuals within a society. Individuals in this demographic group utilize IBS treatment to manage gastrointestinal symptoms associated with aging, addressing age-related changes in digestive health and promoting a better quality of life by alleviating discomfort and supporting overall well-being. As reported in October 2022 by the World Health Organization (WHO), the global population of individuals aged 60 years and older is rapidly growing and is expected to double by 2050, reaching 2.1 billion. Hence, the aging population is a significant driver for the growth of the IBS treatment market.

A prominent trend in the irritable bowel syndrome (IBS) market is the focus on product innovations by major players. Leading companies in the IBS market are actively engaged in developing new and advanced products to reinforce their market positions. For instance, in April 2022, Ardelyx, a U.S.-based biotechnology company, introduced IBSRELA, a first-in-class treatment for IBS-C in adults. IBSRELA, the first and only NHE3 inhibitor available for treating adult irritable bowel syndrome with constipation (IBS-C), offers a novel mechanism therapy for IBS-C and represents a significant new treatment option for constipation, bloating, and stomach pain associated with this debilitating disorder.

Major companies in the irritable bowel syndrome (IBS) market are adopting a strategic partnership approach to address conditions such as Crohn's disease and ulcerative colitis. Strategic partnerships involve collaboration between companies to leverage each other's strengths and resources for mutual benefits. In October 2023, Sanofi S.A., a France-based pharmaceutical industry company, formed a partnership with Teva Pharmaceutical Industries Ltd., an Israel-based pharmaceutical company, aiming to provide treatment for inflammatory bowel disease.

In October 2023, Roche, a Switzerland-based healthcare company, acquired Telavant Holdings for an undisclosed amount. Through this acquisition, Roche gains the rights to develop, manufacture, and market a novel treatment for Irritable Bowel Syndrome (IBS) in the United States and Japan. Telavant Holdings, a U.S.-based biotechnology company, specializes in developing and commercializing innovative therapies for inflammatory and fibrotic diseases.

Major companies operating in the irritable bowel syndrome (IBS) treatment market include Pfizer Inc., Johnson & Johnson Services Inc., AbbVie Inc., Novartis AG, AstraZeneca plc, Abbott Laboratories, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Astellas Pharma Inc., Biogen Inc., Bausch Health Companies Inc., Ironwood Pharmaceuticals Inc., Sebela Pharmaceuticals Inc., Prometheus Laboratories Inc., RedHill Biopharma Ltd., Ardelyx Inc., Cosmo Technologies Ltd., Renexxion Ireland Ltd., 4D Pharma plc, Biora Therapeutics Inc.

North America was the largest region in the irritable bowel syndrome (IBS) treatment market in 2024. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the irritable bowel syndrome (ibs) treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the irritable bowel syndrome (ibs) treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The irritable bowel syndrome (IBS) treatment market includes revenues earned by entities by providing services such as consultation, cognitive-behavioral therapy (CBT), hypnotherapy, psychological therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The irritable bowel syndrome (IBS) market also includes sales of antispasmodics, fiber supplements, laxatives, probiotics, and certain medications targeting gut function. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Irritable Bowel Syndrome (IBS) Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on irritable bowel syndrome (ibs) treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for irritable bowel syndrome (ibs) treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The irritable bowel syndrome (ibs) treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Irritable Bowel Syndrome (IBS) Treatment Market Characteristics

3. Irritable Bowel Syndrome (IBS) Treatment Market Trends And Strategies

4. Irritable Bowel Syndrome (IBS) Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Irritable Bowel Syndrome (IBS) Treatment Growth Analysis And Strategic Analysis Framework

6. Irritable Bowel Syndrome (IBS) Treatment Market Segmentation

7. Irritable Bowel Syndrome (IBS) Treatment Market Regional And Country Analysis

8. Asia-Pacific Irritable Bowel Syndrome (IBS) Treatment Market

9. China Irritable Bowel Syndrome (IBS) Treatment Market

10. India Irritable Bowel Syndrome (IBS) Treatment Market

11. Japan Irritable Bowel Syndrome (IBS) Treatment Market

12. Australia Irritable Bowel Syndrome (IBS) Treatment Market

13. Indonesia Irritable Bowel Syndrome (IBS) Treatment Market

14. South Korea Irritable Bowel Syndrome (IBS) Treatment Market

15. Western Europe Irritable Bowel Syndrome (IBS) Treatment Market

16. UK Irritable Bowel Syndrome (IBS) Treatment Market

17. Germany Irritable Bowel Syndrome (IBS) Treatment Market

18. France Irritable Bowel Syndrome (IBS) Treatment Market

19. Italy Irritable Bowel Syndrome (IBS) Treatment Market

20. Spain Irritable Bowel Syndrome (IBS) Treatment Market

21. Eastern Europe Irritable Bowel Syndrome (IBS) Treatment Market

22. Russia Irritable Bowel Syndrome (IBS) Treatment Market

23. North America Irritable Bowel Syndrome (IBS) Treatment Market

24. USA Irritable Bowel Syndrome (IBS) Treatment Market

25. Canada Irritable Bowel Syndrome (IBS) Treatment Market

26. South America Irritable Bowel Syndrome (IBS) Treatment Market

27. Brazil Irritable Bowel Syndrome (IBS) Treatment Market

28. Middle East Irritable Bowel Syndrome (IBS) Treatment Market

29. Africa Irritable Bowel Syndrome (IBS) Treatment Market

30. Irritable Bowel Syndrome (IBS) Treatment Market Competitive Landscape And Company Profiles

31. Irritable Bowel Syndrome (IBS) Treatment Market Other Major And Innovative Companies

32. Global Irritable Bowel Syndrome (IBS) Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Irritable Bowel Syndrome (IBS) Treatment Market

34. Recent Developments In The Irritable Bowel Syndrome (IBS) Treatment Market

35. Irritable Bowel Syndrome (IBS) Treatment Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기